The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2023 | The impact of autoSCT on disease burden in patients with myeloma treated with quadruplet therapy
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses the importance of reducing the toxicities and risks associated with autologous stem cell transplantation (autoSCT) in patients with multiple myeloma, and further comments on trials evaluating the impact of quadruplet induction therapy. Dr Costa highlights the MIDAS trial (NCT04934475) and the MASTER-2 trial (NCT05231629), and further explains challenges with omitting transplantation in myeloma, as it is still the most effective therapy to achieve MRD negativity despite its toxicities. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
